Form 8-K - Current report:
SEC Accession No. 0000950170-25-038703
Filing Date
2025-03-13
Accepted
2025-03-13 16:03:40
Documents
13
Period of Report
2025-03-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K atyr-20240314.htm   iXBRL 8-K 55288
2 EX-99.1 atyr-ex99_1.htm EX-99.1 190603
3 GRAPHIC img137952089_0.jpg GRAPHIC 44573
  Complete submission text file 0000950170-25-038703.txt   435593

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atyr-20240314.xsd EX-101.SCH 26020
16 EXTRACTED XBRL INSTANCE DOCUMENT atyr-20240314_htm.xml XML 4555
Mailing Address 10240 SORRENTO VALLEY ROAD SUITE 300 SAN DIEGO CA 92121
Business Address 10240 SORRENTO VALLEY ROAD SUITE 300 SAN DIEGO CA 92121 8587318389
aTYR PHARMA INC (Filer) CIK: 0001339970 (see all company filings)

EIN.: 203435077 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37378 | Film No.: 25735669
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)